AstraZeneca to Invest $1.5 Billion in New Singapore Manufacturing Plant
AstraZeneca has announced plans to construct a $1.5 billion manufacturing facility in Singapore, focusing on the production of antibody-drug conjugates (ADCs). The facility, which will be the company's first end-to-end ADC production site, is supported by the Singapore Economic Development Board. ADCs are designed to target tumor cells and release cell-killing chemicals, representing a significant advancement in cancer treatment.
The investment underscores Singapore's status as a leading destination for complex manufacturing due to its robust infrastructure and skilled workforce. AstraZeneca aims to begin the design and construction phase by the end of 2024, with the facility expected to be operational by 2029. The project is part of a broader trend among pharmaceutical companies to localize manufacturing capabilities, ensuring a more reliable and scalable supply of advanced therapeutics.
